According to filings with the U.S. Securities and Exchange Commission, Clarametyx Biosciences is raising up to $33,124,959.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, David Richards played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Clarametyx Biosciences
Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms. Powerful non-antibiotic and pathogen-agnostic biologic technology. CMTX-101 (purple) antibodies capture and remove key linchpin proteins (red), resulting in rapid biofilm collapse. Key modes of action: Immune-enabling: Enables a more efficient immune effector intervention to eliminate disease-causing bacteria. Antibiotic-sensitizing: Enhances the effectiveness of antibiotic activity. Inflammation-suppressing: Decreases biofilm-associated inflammation and reduces inflammatory reaction without impairing immune response

To learn more about Clarametyx Biosciences, visit http://www.clarametyx.com/

Contact:
David Richards, Chief Executive Officer
614-686-2689
https://www.linkedin.com/in/david-v-richards-b8191956/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.